- <![CDATA[Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS]]><![CDATA[TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff. ]]>onclive · 2mo ago↗ source
- <![CDATA[Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and Cancer]]><![CDATA[Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.]]>onclive · 2mo ago↗ source
- Candel reports prostate cancer drug's long-term data ahead of FDA filingCandel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…